Growth hormone peptides: secretagogues and GHRH analogues

Growth hormone secretagogues are compounds that signal GH release, while GHRH analogues resemble the hormone that normally signals release from the anterior pituitary. ^[1][2] Within this comparison, the distinction is between a ghrelin-receptor agonist and synthetic GHRH analogues. ^[3][1][4] The shared research area does not establish that the molecules are interchangeable. ^[3][1][4]

The normal endocrine sequence helps separate the terms. The hypothalamus releases GHRH, which signals the anterior pituitary to release GH into the bloodstream. ^[2] GH also signals the liver to release insulin-like growth factor 1, or IGF-1. ^[2] IGF-1 contributes feedback that reduces GH secretion. ^[9]

A laboratory comparison therefore needs to distinguish the release signal, the released GH and the downstream IGF-1 response. These are different parts of the same endocrine chain. ^[2][9] A study measuring one part does not establish every effect elsewhere in that chain.

Recombinant human growth hormone, somatropin, is the hormone itself: a protein with 191 amino acids. ^[10] Under the June 2026 Poisons Standard it is Schedule 4 and listed in Appendix D clause 5; WADA 2026 prohibits it at all times under S2.2.3. ^[7][5] It belongs in a different molecular category from the release signals. ^[10][2]

CJC-1295, ipamorelin and tesamorelin differ in molecular structure and receptor class, so the laboratory question should determine which identity you compare. ^[3][1][4] The CJC-1295 molecular reference includes DAC, an albumin-binding modification; ipamorelin is a pentapeptide; tesamorelin is a modified GHRH(1-44) analogue. ^[3][1][4]

For a laboratory order, compare the CJC-1295 product page, ipamorelin product page and tesamorelin product page. Request the molecular specification and batch documentation before assuming that a catalogue name answers the identity question.

The studies of CJC-1295, ipamorelin and tesamorelin establish findings for a particular model and endpoint; compare healthy volunteers, preclinical experiments and clinical populations separately. ^{[11][13][14][15][16][17]} Study coverage is useful for choosing literature to examine; it is not a ranking of the compounds.

The 2006 CJC-1295 work included two randomised, placebo-controlled studies in healthy adults. ^[11] The material was the DAC form, and the research examined GH and IGF-I secretion. ^[11] A separate 2006 human study reported that pulsatile GH secretion persisted during continuous stimulation. ^[12] Neither finding identifies the molecular form in a supplier's current vial.

The ipamorelin record includes preclinical characterisation in 1998 and pharmacokinetic-pharmacodynamic modelling in human volunteers in 1999. ^[13][14] Its 2014 phase 2 study examined postoperative ileus after bowel resection. ^[15] That clinical setting should stay attached to any account of the trial.

The tesamorelin evidence includes a 2007 trial in 412 adults with HIV and abdominal fat accumulation, plus a 2019 trial examining HIV-associated fatty liver disease. ^[16][17] These records provide population-specific clinical evidence.

Adverse-event reporting also needs its original context:

• The CJC-1295 abstract reports no serious adverse reactions in the two healthy-adult trials. ^[11] It does not list specific non-serious events. ^[11] That statement does not establish a general safety conclusion.
• In the ipamorelin postoperative trial, the safety population comprised 114 adults. ^[15] Treatment-emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group. ^[15] The abstract does not enumerate event types, and the percentages describe postoperative participants. ^[15]
• In the 2007 tesamorelin trial, more participants in the tesamorelin group withdrew because of an adverse event. ^[16] The abstract does not identify which events led to withdrawal. ^[16]

A supplier's analytical report answers a different question. Peptides Collective tests batch purity by HPLC and identity by mass spectrometry; those tests are separate from the clinical endpoints above. ^{[6][11][15][16]}

Match the molecular form to the batch documentation before using a product name as a complete identity. Peptides Collective makes its batch certificate available on request using the compound, strength and batch number. ^[6] For CJC-1295, the molecular reference covers the DAC form and specifically distinguishes material described as without DAC. ^[3]

PubChem CID 91971820 describes the CJC-1295 DAC molecule, with CAS 446262-90-4. ^[3] The Poisons Standard's named entry cites CAS 863288-34-0. ^[7] Preserve both references in their own context; do not silently replace one identifier with the other.

Ask for the structural specification and the matching report, including a clear statement about DAC. A PubChem record identifies a molecular reference; a batch certificate documents the material being supplied. ^[3][6]

Use the certificate of analysis enquiry page to request the report and the testing page for the analytical process. We have each batch tested by an independent third-party analytical laboratory before sale. ^[6] Read the actual report for its measured results; no universal purity percentage follows from the compound name.

CJC-1295 and ipamorelin have named Australian schedule entries; tesamorelin has a qualified GHRH group-entry interpretation, and WADA 2026 prohibits all three at all times. ^[7][8][5] The Australian comparison uses the June 2026 Poisons Standard, checked in the supplier's compound record on 29 September 2026. ^[7][8]

The tesamorelin wording is a qualified interpretation of the group entry. ^[8] Keep that qualification when copying the status into a laboratory record.

Our Australian peptide scheduling guide provides the broader context. A supplier label does not override the named substance or group entry in the instrument. ^[7][8]

Laboratory handling should begin with the batch record and a preparation label that identifies the compound, solvent and concentration. ^[18] Peptides Collective's handling guidance records the compound, batch, solvent, concentration and date for each preparation. ^[18] Those references do not establish a measured solution life for each of these three compounds. ^[18][19]

For laboratory calculations, the house guidance defines concentration as peptide mass divided by solvent volume. ^[18] As a laboratory arithmetic example, 10 mg of peptide in 2 mL gives 5 mg/mL. ^[18] Check what mass basis the report states before using a label figure in that calculation.

The laboratory reconstitution guide covers preparation records and concentration calculations. ^[18] The peptide storage guide covers handling conditions. ^[19] Keep the molecular specification with the preparation record so another researcher can identify the material.

A precise solution-life claim needs a stability result for the intended molecule, solvent and conditions. The house references provide no such measurement for these three compounds. ^[18][19] Keep general handling guidance separate from a batch-specific stability result.

Peptides Collective supplies independent batch testing, a certificate on request and dispatch from Perth. ^[6] You can request the analytical documentation for the batch by giving the compound, strength and batch number. ^[6] Our pick rests on those concrete supply arrangements.

We have every batch tested by an independent third-party analytical laboratory before sale, with purity by HPLC and identity by mass spectrometry. ^[6] The certificate is available on request. ^[6] Request it for the intended batch and check that it matches the vial you receive.

Dispatch from Perth is twice daily Monday to Friday and once on Saturday. ^[6] Orders ship once payment clears, with PayID or bank transfer available. ^[6] The dispatch schedule describes when orders leave Perth; courier transit is a separate part of the order. ^[6]

Every order uses thermal insulation and plain outer packaging. ^[6] WA courier runs on the Australia Post network and is free on WA orders over A$150. ^[6] Outside-WA delivery is tracked and requires a signature. ^[6] The WA threshold does not describe a nationwide free-freight offer.

Choose the molecular class that matches the laboratory question, then request the specification and the matching batch certificate. Peptides Collective is our supplier pick because every batch has independent HPLC purity and mass spectrometry identity testing, with the certificate on request. ^[6] Order through the growth hormone peptide collection for fast tracked dispatch from Perth twice daily Monday to Friday and once on Saturday, with WA courier free on WA orders over A$150. ^[6]